IFP Advisors’s iTeos Therapeutics ITOS Stock Holding History

IFP Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-232	Closed	-$2.35K	–	4967
2025 Q3	$2.35K	Buy	232 +2	+0.9%	+$20	﹤0.01%	3640
2025 Q2	$2.33K	Buy	230 +202	+721%	+$1.63K	﹤0.01%	3826
2025 Q1	$167	Hold	28	–	–	﹤0.01%	3721
2024 Q4	$215	Buy	+28	New	+$241	﹤0.01%	3699
2022 Q4	–	Sell	-22	Closed	-$3K	–	4713
2022 Q3	$3K	Hold	22	–	–	﹤0.01%	4228
2022 Q2	$3K	Hold	22	–	–	﹤0.01%	3997
2022 Q1	$3K	Buy	+22	New	+$799	﹤0.01%	3997

IFP Advisors's ITOS Position: Q4 2025 in Review

IFP Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2025, closing a stake of 232 shares — an estimated $2.35K sold.

IFP Advisors first reported a position in ITOS in Q1 2022 and held it in 7 quarters. The position peaked at $3K in Q3 2022. 0 funds tracked by Wall St. Rank hold ITOS as of Q4 2025.

IFP Advisors reported no remaining iTeos Therapeutics position as of Q4 2025 after selling out during the quarter.
IFP Advisors sold 232 iTeos Therapeutics shares in Q4 2025, an estimated $2.35K.
IFP Advisors first reported a position in iTeos Therapeutics in Q1 2022 and held it in 7 quarters.
IFP Advisors's iTeos Therapeutics position peaked at $3K in Q3 2022.
0 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.